

. (37 CFR 1.98(d))

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Stacey Ann JONES et al.

[] Copies of the references are enclosed

whichever occurs first.

Disclosure Statement under § 1.97(c) (\$180.00).

Serial No.: To be assigned

Filing Date: Concurrently herewith

or: Compositions and Methods for Treatment of Fibrosis

Mail Stop PCT (DO/EO/US) Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

A. [X]

В.

[]

[]

Art Unit: To be assigned Examiner: To be assigned

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97.

[X] A copy of the International Search Report which issued on International Application No.

PCTV25004/029748 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached from PTO-1449 and Applicants understand that

copies have been supplied to the U.S. Patent Office by the International Bureau.

[] Copies of the references were submitted in parent application Serial No. _

	filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).						
OR	**						
[]	The Information Disclosure Statement submitted berewith is being filed before the mailing of a first office action after the filling of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).						
[]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either: (1) a final action under § 1.113 or						

Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information

The Information Disclosure Statement submitted herewith is being filed within three months of the

IAP20 RCS'dF STATO 22 MAR 2006

C. [] The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.11, so ran ontice of allowance under § 1.31, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- [] Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement, and
- [] The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No.07-1392.

[] A duplicate copy of this paper is attached.

Respectfully Submitted,

Attorney of Record Registration No. 43.941

Date: March Dy 7006

GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8961 Facsimile: (919) 483-7977

FORM PTO INFORMA		DISCLOSURE S	FATEMENT	ATTORNEY DOCKET NO. SERIAL NO. 2974 PR60397USW MORE APPLICANT Stacey Ann JONES et al.					
					FILING DATE Concurrently herewith		GROUP To be assigned		
			U.S.	PATENT I	OCUMENTS	nerewith	10 be assi	gueu	
Examiner Initials				Name	Class	Subclass	Filing Date If Appropriate		
				Ontinue on	page T DOCUMENT	S			
		Document Number	Publication Date		Country	Class	Subclass	Translation Yes No	
/A.P./	1.	WO 00/37077	06/29/2000	PCT					
							-		
		OTHER DOCU		ontinue on		Date, Page Nur	nber, Etc.)		
	F			-	,		,,		

	1								
	Ħ								
		-							
	Ь	. I		Continue or	page				
EXAMINE	EXAMINER /Anna Pagonakis/						DATE CONSIDERED 05/28/2009		
EXAMINE citation if no	R: Init	ial if citation consident	ered, whether or considered. Incl	not citation	is in conformant	e with MPEP §	609; Draw lin	e through icant.	